Asset and Long-term Investment Impairment Charges

6 Months Ended

Jun. 30, 2017

Asset And Long Term Investment Impairment Charges [Abstract]

Asset and Long-term Investment Impairment Charges

7. Asset and Long-term Investment Impairment Charges

We incurred the following asset and long-term investment impairment charges:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2017		2016		2017		2016
Asset impairment charges	$	0	$	0	$	0	$	4,650
Impairment of long-term investments	$	144,590	$	0	$	144,590	$	0

During the first quarter of 2016, we incurred non-cash asset impairment charges which included $2.2 million for the impairment of capitalized software as a result of our decision to discontinue several software development projects, $2.1 million for the impairment of one of our cost method equity investments, and other charges of $0.4 million to write down a long-term asset to its estimated net realizable value.

During the three months ended June 30, 2017, we recognized other-than-temporary non-cash impairment charges of $144.6 million associated with two of the Company’s long-term investments based on management’s assessment of the likelihood of near-term recovery of the investments’ value. The majority of the impairment charges relate to our investment in NantHealth common stock. Refer to Note 3, “Fair Value Measurements and Long-term Investments” and Note 11, “Other Comprehensive Income,” for further information regarding these impairments. Refer to Note 15, “Subsequent Events,” for information regarding our agreement to divest our investment in NantHealth common stock.